Overview

Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.

Status:
Completed

Trial end date:
2020-11-16

Target enrollment:

Participant gender:

Summary

CALAVI US will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Collaborators:

Acerta Pharma B.V.
Acerta Pharma BV

Treatments:

Acalabrutinib